Your browser doesn't support javascript.
loading
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Johnson, Douglas B; Bordeaux, Jennifer; Kim, Ju Young; Vaupel, Christine; Rimm, David L; Ho, Thai H; Joseph, Richard W; Daud, Adil I; Conry, Robert M; Gaughan, Elizabeth M; Hernandez-Aya, Leonel F; Dimou, Anastasios; Funchain, Pauline; Smithy, James; Witte, John S; McKee, Svetlana B; Ko, Jennifer; Wrangle, John M; Dabbas, Bashar; Tangri, Shabnam; Lameh, Jelveh; Hall, Jeffrey; Markowitz, Joseph; Balko, Justin M; Dakappagari, Naveen.
Afiliación
  • Johnson DB; Vanderbilt University Medical Center, Nashville, Tennessee. douglas.b.johnson@vanderbilt.edu.
  • Bordeaux J; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
  • Kim JY; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
  • Vaupel C; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
  • Rimm DL; Yale University, New Haven, Connecticut.
  • Ho TH; Mayo Clinic, Jacksonville, Florida and Phoenix, Arizona.
  • Joseph RW; Mayo Clinic, Jacksonville, Florida and Phoenix, Arizona.
  • Daud AI; University of California, San Francisco, California.
  • Conry RM; University of Alabama, Birmingham, Alabama.
  • Gaughan EM; University of Virginia, Charlottesville, Virginia.
  • Hernandez-Aya LF; Washington University in St. Louis, St. Louis, Missouri.
  • Dimou A; Medical University of South Carolina, Charleston, South Carolina.
  • Funchain P; Cleveland Clinic, Cleveland, Ohio.
  • Smithy J; Yale University, New Haven, Connecticut.
  • Witte JS; University of California, San Francisco, California.
  • McKee SB; University of Alabama, Birmingham, Alabama.
  • Ko J; Cleveland Clinic, Cleveland, Ohio.
  • Wrangle JM; Medical University of South Carolina, Charleston, South Carolina.
  • Dabbas B; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
  • Tangri S; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
  • Lameh J; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
  • Hall J; Genoptix, Inc., Carlsbad, California.
  • Markowitz J; Moffitt Cancer Center, Tampa, Florida.
  • Balko JM; Vanderbilt University Medical Center, Nashville, Tennessee.
  • Dakappagari N; Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
Clin Cancer Res ; 24(21): 5250-5260, 2018 11 01.
Article en En | MEDLINE | ID: mdl-30021908
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos HLA-DR / Indolamina-Pirrol 2,3,-Dioxigenasa / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 / Melanoma Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos HLA-DR / Indolamina-Pirrol 2,3,-Dioxigenasa / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 / Melanoma Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos